Overview

RecurX Bio's phenotypic microfluidic assay captures the deadly cell sub population responsible for cancer metastasis and rapid spread. Our test is used to uncover and discover the best existing and new cancer drugs to stop these deadly cells before treatment or clinical trials begin. Currently there are few tests that provide oncologists with sufficient information to know which drugs will work best for an individual patient. Current practice is to choose based mainly on which drug has the least side effects and then wait to see if the cancer responds. This treatment strategy can cause the patient serious unnecessary side effects from drugs that don't work, and cost valuable time in the race to stop the cancer. Our technology can provide personalized information to oncologists within a couple of days. We are seeking to collaborate with pharmaceutical companies to provide more effective drug development. Approximately 97%+ of cancer drugs fail in development and clinical trials, in part because laboratory models do not accurately represent what happens in the body during metastasis. Better technology is necessary to bring much needed drugs to market. New drug discovery can potentially can occur faster, less expensively and with greater success using RecurX Bio's technology. Our technology is designed to screen and select drug candidates for preclinical and clinical testing and to identify unique druggable targets in the most deadly cells captured by our technology. Our research in breast cancer and glioblastoma has been published, and we plan to develop the test for additional solid and liquid tumors. See Yankaskas, et al. A microfluidic assay for the quantification of the metastatic propensity of breast cancer Nat Biomed Eng 3, 452 - 465 (2019); Wong, et al. A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma. Nat Biomed Eng (2020) https://doi.org/10.1038/s41551-020-00621-9